DEFJ, LLC and CK Life Sciences Int'l., (Holdings) Inc. Acquire 9.1% Stake in TransCode Therapeutics, Inc.

DEFJ, LLC and CK Life Sciences Int'l., (Holdings) Inc. have jointly filed a Schedule 13D to disclose their acquisition of a 9.1% stake in TransCode Therapeutics, Inc. The acquisition was completed through a Membership Interest Purchase Agreement and an Investment Agreement, which involved the issuance of common stock and preferred stock to DEFJ. The preferred stock is convertible into common stock, and DEFJ also received a promissory note as part of the transaction. The filing also details various agreements, including a Contingent Value Rights Agreement, a Registration Rights Agreement, and a Repurchase Agreement. The Reporting Persons have indicated that they may consider additional transactions involving TransCode Therapeutics, Inc. in the future, depending on market conditions and other factors.